(Q37445006)

20 August 2017

1 reference

title

Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments (English)

1 reference

20 August 2017

1 reference

1 reference

Rudolph M Navari

1

1 reference

20 August 2017

publication date

1 January 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

69

1 reference

20 August 2017

issue

5

1 reference

20 August 2017

page(s)

515-533

1 reference

The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical

20 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200969050-00002

Potential of substance P antagonists as antiemetics

21 January 2018

1 reference

12 December 2020

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

1 reference

12 December 2020

Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference

1 reference

12 December 2020

Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects

1 reference

12 December 2020

Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting

1 reference

12 December 2020

Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence

1 reference

12 December 2020

Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists

1 reference

12 December 2020

The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets

1 reference

12 December 2020

Prevention of emesis from multiple-day and high-dose chemotherapy regimens

1 reference

12 December 2020

Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy

1 reference

12 December 2020

Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory.

1 reference

12 December 2020

Effects of CP-99, 994, a tachykinin NK(1) receptor antagonist, on abdominal afferent vagal activity in ferrets: evidence for involvement of NK(1) and 5-HT(3) receptors

1 reference

12 December 2020

A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis

1 reference

12 December 2020

Chemotherapy-induced nausea and vomiting: state of the art in 2006.

1 reference

12 December 2020

Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine

1 reference

12 December 2020

Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin

1 reference

12 December 2020

Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone

1 reference

12 December 2020

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 St

1 reference

12 December 2020

Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and anti-nausea activities

1 reference

12 December 2020

American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

1 reference

12 December 2020

Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment

1 reference

12 December 2020

Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings

1 reference

12 December 2020

Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group

1 reference

12 December 2020

Brain uptake and receptor binding of two [11C]labelled selective high affinity NK1-antagonists, GR203040 and GR205171--PET studies in rhesus monkey

1 reference

12 December 2020

Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.

1 reference

12 December 2020

Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Em

1 reference

12 December 2020

Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin

1 reference

12 December 2020

A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study

1 reference

12 December 2020

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron

1 reference

12 December 2020

[Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer]

1 reference

12 December 2020

Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer.

1 reference

12 December 2020

Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets

1 reference

12 December 2020

Incidence of chemotherapy-induced nausea and emesis after modern antiemetics

1 reference

12 December 2020

Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? An observational study

1 reference

12 December 2020

Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group

1 reference

12 December 2020

A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study

1 reference

12 December 2020

A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy

1 reference

12 December 2020

Mechanism of action of cannabinoids: how it may lead to treatment of cachexia, emesis, and pain.

1 reference

12 December 2020

Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment

1 reference

12 December 2020

Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis

1 reference

12 December 2020

5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial

1 reference

12 December 2020

Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group.

1 reference

12 December 2020

Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting

1 reference

12 December 2020

Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis

1 reference

12 December 2020

Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide:.

1 reference

12 December 2020

Identification and functional characterization of brainstem cannabinoid CB2 receptors

1 reference

12 December 2020

Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo

1 reference

12 December 2020

Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III ran

1 reference

12 December 2020

Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis

1 reference

12 December 2020

Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.

1 reference

12 December 2020

Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications

1 reference

12 December 2020

Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.

1 reference

12 December 2020

Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting

1 reference

12 December 2020

A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study

1 reference

12 December 2020

Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.

1 reference

12 December 2020

[Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP]

1 reference

12 December 2020

The pathophysiology of chemotherapy-induced nausea and vomiting

1 reference

12 December 2020

Why Do We Need Another Antiemetic? Just Ask

1 reference

12 December 2020

Delayed emesis: moderately emetogenic chemotherapy

1 reference

12 December 2020

Radioreceptor binding profile of the atypical antipsychotic olanzapine.

1 reference

12 December 2020

Effects of 5-HT3 receptor antagonists on models of acute and delayed emesis induced by cisplatin in the ferret.

1 reference

12 December 2020

Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. Italian Group for Antiemetic Research

1 reference

12 December 2020

Antipsychotic-induced weight gain: a review of the literature

1 reference

12 December 2020

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America

1 reference

12 December 2020

Antiemetic guidelines: creating a more practical treatment approach

1 reference

12 December 2020

Neurons in the nucleus of the solitary tract mediating inputs from emetic vagal afferents and the area postrema to the pattern generator for the emetic act in dogs

1 reference

12 December 2020

Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy

1 reference

12 December 2020

Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy

1 reference

12 December 2020

Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting

1 reference

12 December 2020

Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study

1 reference

12 December 2020

New treatment options for chemotherapy-induced nausea and vomiting

1 reference

12 December 2020

Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treate

1 reference

12 December 2020

Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis

1 reference

12 December 2020

Antiemetic effects of sendide, a peptide tachykinin NK1 receptor antagonist, in the ferret

1 reference

12 December 2020

New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment

1 reference

12 December 2020

Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer

1 reference

12 December 2020

Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis

1 reference

12 December 2020

Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--an update.

1 reference

12 December 2020

Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy

1 reference

12 December 2020

Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer

1 reference

12 December 2020

Organization of vestibular inputs to nucleus tractus solitarius and adjacent structures in cat brain stem

1 reference

12 December 2020

Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting

1 reference

12 December 2020

10.2165/00003495-200969050-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

20 August 2017

1006462768

0 references

1 reference